Fulgent Announces 2026 Revenue Guidance and Advances AI Diagnostic Integration
Fulgent (FLGT) has provided full-year 2026 revenue guidance of $330 million to $340 million following its third-quarter earnings report. The company reported a strong cash position of $652.4 million, bolstered by a federal tax refund, which provides significant financial flexibility as laboratory collections continue to recover from previous billing software transition delays. Key operational highlights include the rapid scaling of Fulgent's diagnostic AI platform, which saw a 23% sequential increase in slide image analysis volume with a technical failure rate of only 0.01%. Additionally, the company is advancing its oncology pipeline, specifically moving its nanoencapsulated therapy candidate FID-007 closer to Phase 3 clinical trials following discussions with the FDA.

Tickers: $FLGT
Topics: artificial intelligence cash reserves earnings report laboratory services revenue guidance
Read the full article at Motley Fool
Part of the story Fulgent Announces 2026 Revenue Guidance and Advances AI Diagnostic Integration (7 articles)